期刊文献+

CTSD基因表遗传学修饰与乳腺癌转移的关系

Epigenetic modification of CTSD gene with breast cancer
下载PDF
导出
摘要 目的:检测乳腺癌组织CTSD基因增强子区遗传和表遗传学改变,探讨其与乳腺癌转移的关系。方法:取152例乳腺癌标本及对应的癌旁组织,采用PCR扩增技术对CTSD基因增强子区进行扩增,产物进行基因测序。应用甲基化特异性限制性内切酶酶切联合PCR扩增技术,观察乳腺癌组织CTSD基因增强子区去甲基化状态。结果:遗传学改变研究表明,CTSD基因增强子区基因片段测序结果显示未发现有意义的突变位点。表遗传研究表明,转移乳腺癌组织中增强子区去甲基化发生率为85.3%,癌旁组织为0,两者差别有显著统计学意义(P<0.05)。未转移乳腺癌去甲基化发生率为51.9%,相较于癌旁组织,差别有统计学意义(P<0.05)。转移和未转移乳腺癌去甲基化发生率相比,差别也有统计学意义(P<0.05)。结论:CTSD基因增强子区的功能调控不受遗传学突变的影响,其去甲基化率与乳腺癌的转移有关,有望成为乳腺癌的一个预后指标。 Objective:To explore the relationship between genetic and epigentic modification of CTSD gene enhancer and breast cancer metastasis.Methods:CTSD gene enhancer sequence was detected in 152 cases of breast cancer specimens and paracancerous tissues using PCR amplification.CTSD gene enhancer demethylation state was observed in breast cancer by methylation-specific re-striction enzyme digestion combined with PCR amplification.Results:There is no meaningful mutational site in CTSD gene enhancer sequencing.Our genetic research shows that incidence of methylation are 85.3% in metastatic breast cancer enhancer and 51.9% in non metastatic breast cancer.However no methylation is observed in paracancerous tissues.So both of the methylation incidence in metastatic and non-metastatic tissues are significantly different from that in paracancerous tissues.Conclusion:The functional regula-tion in CTSD gene enhancer does not suffer from the influence of genetic mutations.The demethylation incidence in CTSD enhancer is high related to metastasis of breast cancer.Therefore,demethylation level in CTSD gene enhancer may be the prognostic indicator of breast cancer.
作者 李丽 唐金海
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第8期1188-1191,共4页 Journal of Nanjing Medical University(Natural Sciences)
关键词 CTSD基因 增强子 去甲基化 乳腺癌 预后 组织蛋白酶 CTSD gene; enhancer; demethylation; breast cancer; prognosis; cathepsin;
  • 相关文献

参考文献14

  • 1Duffy MJ. Proteases as prognostic markers in cancer[J].Clin Cancer Res, 1996,2 (4) : 613-618.
  • 2吴凤云,刘运江.组织蛋白酶D在乳腺癌浸润转移中作用的研究[J].肿瘤防治研究,2004,31(12):730-732. 被引量:3
  • 3Glondu M,Liaudet-Coopman E,Derocq D,et al. Downregulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells [J]. Oncogene, 2002,21 (5) : 27-34.
  • 4Nancy B,Sara K,Martin Seifert,et al. E2-mediated cathepsin D (CTSD) activation involves looping of distal enhancer elements [ J ]. Molecular Oncology, 2008,2 (2) : 152-190.
  • 5Redecker B,Heckendorf B, Grosch HW,et al. Molecular organization of the human cathepsin D gene [J]. DNA Cell Biol, 1991, (10) :423-431.
  • 6Alina Minarowska, Marek Gacko,Alicja Karwowska,et al. Human cathepsin D [J]. Folia Histochemical et Cytobiological, 2008,46( 1 ) :23-38.
  • 7Rochefort H,Garcia M,Glondu M,et al. Catthepsin D in braest cancer:mechanisms and clinical applications,a 1999 overview [J]. Clin Chim Acta,2000,291 (2):157- 170.
  • 8Jones PA,Takai D. The role of DNA methylation in mammalian epigenetics [ J ]. Science, 2001,29 (3) : 1068-1070.
  • 9邵志敏,江明,沈镇宙.生化法检测组织蛋白酶-D在淋巴结阴性乳腺癌中的预后作用[J].中国癌症杂志,1997,7(2):97-100. 被引量:4
  • 10May FE, Smith DJ,Westley BR. The human cathepsin D-encoding gene is transcribed from an estrogen-regulated anda constitutive start point[J]. Gene, 1993,13 (4) :277- 282.

二级参考文献7

  • 1Gaci Z, Bouin-Pineau MH, Gaci M, et al. Prognostic impact of cathepsin D and C-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors[J].Int J Oncol, 2001,18(4): 793-800.
  • 2Glondu M, Liaudet - Coopman E, Derocq D, et al. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells[J]. Oncogene, 2002,21(33): 5127-5134.
  • 3Rochefort H, Garcia M, Glondu M, et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview[J]. Clin Chim Acta, 2000, 291(2): 157-170.
  • 4Read W, Hannisdal E. The prognostic value of p53 and c-erbB-2immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in613 patients with a follow-up of 30~64 years[J]. Cancer, 2000
  • 5Roger P, Daures JP, Maudelonde T, et al. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors[J]. Hum Pathol, 2000,31(5): 593-600.
  • 6Jahkola T, Toivonen T, von Smitten K, et al. Cathepsin D,urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors[J].B
  • 7Pugol P, Daures JP, Brouillet JP, et al. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer [J]. Br J Cancer, 1999, 79 (5-6): 909-914.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部